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Conclusions: An IL-20 ELISA has been developed and further samples 
are being collected for analysis. Based on these ﬁndings that IL-20 is 
up-regulated by TSA and under epigenetic control, targeting this cy-
tokine may be used as a potential anti-angiogenic approach in making 
lung cancer history.
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A number of growth-factor-receptor-targeted agents have been tried 
with encouraging results in patients with advanced NSCLC (Noble et 
al 2006). Women, non-smokers, adenocarcinoma and Asians respond 
better. This communication is our further experience of our earlier 
presentation. 
Histologically proven advanced (stage IIIB or IV) non-small cell lung 
cancer patients earler treated with chemotherapy received geﬁtinib 
(Geﬁtinat) 250mg daily orally. There were 28 females (38-57 yrs) and 
67 males (44-67 yrs). Fifty four were non-smokers and the remaining 
were smokers. Sixty two had adenocarcinoma and 33 had squamous 
cell carcinoma. The disease was of stage IIIB (n=58) and stage IV 
(n=37). The duration of geﬁtinib therapy varied from 20 weeks to 58 
weeks with median of 29.5 weeks. The disease remained static in 66 
(69%) with stabilization or improvement in the Kornofsky performance 
scales in 73. The mean performance status improved from 70 to 90 
in 34 cases, deteriorated in 13 and in the remaining remained static at 
90. There was no radiological progression in 43 cases, while 28 cases 
showed radiological progression. The median survival (calculated after 
completion of chemotherapy and start of geﬁtinib) was 33 weeks with 
22 patients surviving beyond 1 year. The drug was well tolerated by 
all. Thirty three patients complained of mild skin rash (three ﬁxed drug 
eruption). 29 patients had grade 1-2 diarrhoea. 
We found geﬁtinib as beneﬁcial The drug is well tolerated by Indian 
patients.This may be due to a different pharmacogenomic property of 
geﬁtinib in this population. 
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Background: VEGF expression has been correlated with increased 
tumor angiogenesis and shortened survival in NSCLC, and inhibition 
of the VEGF and also the EGF signaling pathways has a demonstrated 
treatment beneﬁt in this malignancy. Therefore, a treatment strategy 
combining agents that speciﬁcally inhibit both signaling pathways may 
further improve patient outcome. Sunitinib malate is an oral, multitar-
geted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET and 
FLT3, approved multinationally for the treatment of advanced renal cell 
carcinoma and imatinib-resistant or -intolerant gastrointestinal stromal 
tumor. A multicenter phase II trial of sunitinib administered on a 4/2 
schedule (4 weeks on treatment followed by 2 weeks off) in recurrent 
advanced NSCLC demonstrated an 11% objective response rate among 
patients treated second- or third-line (Socinski, ESMO 2006). Here 
we report the results of a lead-in safety study assessing the safety and 
tolerability of sunitinib combined with erlotinib in locally advanced or 
metastatic NSCLC after failure of chemotherapy. If the safety proﬁle 
of the combination is favorable, 126 patients will be randomized to 
sunitinib plus erlotinib or to placebo plus erlotinib in a phase II portion 
of the study.
Methods: The lead-in safety cohort was planned to include 10 patients 
evaluable for the safety and tolerability of sunitinib combined with 
erlotinib, with additional patients enrolled if needed to obtain adequate 
pharmacokinetic data. Patients were eligible if they had histologically 
proven, stage IIIB or IV NSCLC; had received 1 or 2 prior chemothera-
py regimens, including a platinum-based regimen; measurable disease; 
ECOG PS 0 or 1, and adequate organ function. Treatment comprised 
sunitinib 37.5 mg/day continuously plus erlotinib 150 mg/day, given 
orally, in repeated 4-week cycles. Patients were observed for dose-lim-
iting toxicities (DLTs) during the ﬁrst 28 days of treatment.
Results: Twelve patients were treated in the lead-in cohort, with the 
following baseline characteristics: median age 62 years (range 47-75); 
6 male; histology 9 adenocarcinoma, 1 squamous cell carcinoma, 2 
other; history of smoking in 8 patients. The patients started a median of 
2 cycles (range 1-5), with dose reductions in 5 patients (erlotinib, n=2; 
sunitinib, n=1; both, n=2). Two patients developed a DLT (both grade 3 
fatigue lasting at least 7 days). Adverse events were generally mild-to-
moderate in severity (grade 1/2). Seven patients experienced grade 3 
adverse events that included diarrhea (n=3), fatigue (n=2), acne (n=1), 
anemia (n=1), dehydration (n=1), diffuse skin rash (n=1), pruritus 
(n=1) and paronychial inﬂammation (n=1); no grade 4/5 events were 
reported. Pharmacokinetic analyses are ongoing.
Conclusions: Sunitinib 37.5 mg/day given continuously with erlo-
tinib 150 mg/day was safe and tolerable in this cohort of patients with 
advanced NSCLC. The efﬁcacy and safety of sunitinib combined with 
erlotinib will be investigated further in the randomized phase II portion 
of this study. 
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Background: In non-small cell lung cancer (NSCLC) preclinical 
models, celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates 
the apoptotic and growth inhibitory effects of erlotinib, an epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). We 
designed a phase II trial to evaluate the clinical efﬁcacy and safety of 
erlotinib plus celecoxib in advanced NSCLC. 
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Methods: Patients with NSCLC who had received one prior che-
motherapy regimen were treated with celecoxib, 400mg twice daily, 
orally, and erlotinib, 150mg daily, orally, until disease progression. The 
planned accrual was 40 patients. Tissue was collected for EGFR analy-
sis and COX-2 staining by immunohistochemistry (IHC). 
Results: Twenty-six patients with stage IIIB/IV NSCLC were enrolled. 
Patient characteristics: male 65%; median age 66; ECOG performance 
status 0/1- 96%. Tissue was available for FISH and EGFR muta-
tion analysis for 18 patients and for COX-2 IHC for 21 patients. Two 
patients had a partial response (PR) and 8 patients had stable disease 
(SD). The median progression free survival (PFS) and overall survival 
(OS) were 1.9 and 10.2 months, respectively. Fifty percent of tested pa-
tients had chromosome 7 polysomy without a correlation with response 
or PFS. Eleven patients (52% of tested) had tumors with increased 
COX-2 expression which was strongly associated with prolonged PFS, 
p=.008. Two patients had an EGFR mutation present, one had a PR 
(exon 19) and one had progressive disease (exon 21). Four patients 
either on anticoagulation or with a history of peptic ulcer disease had 
Grade 3/4 upper gastrointestinal bleeding, prompting study closure. 
Three of these 4 patients had endoscopy and were found to have peptic 
ulcers. 
Conclusions: In this trial, the combination of erlotinib and celecoxib 
did not result in improved efﬁcacy compared with historical controls 
though it did suggest improved PFS in patients with increased expres-
sion of COX-2. However, the high incidence of gastrointestinal bleed-
ing in this group of patients suggests that the combination of COX-2 
inhibitors and EGFR-TKI should not be given to patients with a previ-
ous history of peptic ulcer disease or to patients requiring therapeutic 
anticoagulation. 
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Clinical and molecular characteristics of advanced non-small cell 
lung cancer (NSCLC) patients (pts) with rapid progressive disease 
(RPD) on gefitinib therapy (G)
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Background: Prognostic factors associated with better outcomes 
(EGFR mutations (mut), high EGFR gene copy number, never smok-
ing) can be used to select pts for EGFR tyrosine kinase inhibitor (TKI) 
combination trials, but would exclude most NSCLC pts. Excluding 
pts with the worst likely outcomes may identify more pts who could 
beneﬁt from combination of a TKI with other agents. Our objective was 
to identify clinical and molecular characteristics associated with RPD 
(≤70 days) and shorter progression-free survival (PFS) in previously 
treated NSCLC pts receiving G.
Methods: Consecutive Expanded Access Trial pts with >1 week 
G were included for analysis. Tissue from 87 pts was evaluated for 
EGFR, pAKT, and PTEN protein expression by immunohistochemistry 
(IHC); 81 tumors were evaluated for gene copy number by ﬂuorescence 
in situ hybridization (FISH); 58 tumors were analyzed for mut and sum 
of CA dinucliotide repeats (∑CArepeats) by SSCP, PCR, and sequenc-
ing. EGFR and centromere 7 (CEN7) probes were utilized to examine 
EGFR/cell and CEN7/cell. Pts were classifed as FISH+ with high poly-
somy (≥4 copies of the EGFR gene in ≥40% of cells) or ampliﬁcation 
(EGFR gene/CEN7 ≥2, or ≥15 copies of EGFR genes per cell in ≥10% 
of cells), or FISH- (≤4 copies of the gene in >40% of cells).
Results: There were 150 pts; 77 female, median (md) age 67. Md fol-
low-up was 5.8 months (mo). Objective response was 8% (2CR, 10PR, 
56SD, 82RPD). Md Kaplan-Meier PFS and survival were 2.0 and 5.8 
mo, respectively. Table displays univariate results. Non-adenocarci-
noma histology (N-A-H), smoking, ≤12 mo from diagnosis to G (dx-
G≤12mo), lack of mut, and ∑CArepeats<34 were associated with RPD. 
Smoking, Mut-PTEN-, EGFR-PTEN-, and EGFR-pAKT- tumors were 
associated with shorter PFS. Separate clinical and molecular multivari-
ate models were developed. In logistic regressions, N-A-H, p=0.004, 
dx-G≤12mo, p=0.0009, lack of mut (p=0.0298), and ∑CArepeats<34 
(p=0.0622) were associated with RPD. In Cox regressions, N-A-H 
(p=0.0256), dx-G≤12mo (p=0.0166), and lack of mut (p=0.0298) were 
associated with shorter PFS. EGFR FISH variables, alone or combined 
with EGFR IHC, were not signiﬁcantly associated with RPD or PFS.
Conclusion: N-A-H, dx-G≤12mo, and lack of mut were associated 
with RPD and shorter PFS in univariate and multivariate analyses. 
∑CArepeats<34 and certain non-FISH double-negative molecular 
combinations were also related to worse outcome. These clinical and 
molecular characteristics may warrant further study as exclusion crite-
ria for TKI combination clinical trials.
Summary of Univariate Analyses
Variable n Pts (%)
n Pts with 
Rapid PD (%)
Chi-sq p Md PFS (mo) Log-rank p
Other histology 65 (43) 44 (68)
0.0051
1.9
0.0383
Adenocarcinoma 85 (57) 38 (45) 2.9
Smoker 130 (87) 75 (58)
0.0577
2.0
0.0013
Never smoked 20 (13) 7 (35) 8.7
≤12 mo from dx to G 88 (59) 58 (66)
0.0010
1.9
0.0233
>12 mo from dx to G 62 (41) 24 (39) 3.4
Mutation absent 41 (71) 18 (44)
0.0050
3.3
0.0010
Mutation present 17 (29) 1 ( 6) 13.6
Mutation- pAKT- 18 (32) 5 (28)
0.5455
4.0
0.4699
Any positive 39 (68) 14 (36) 3.9
Mutation- PTEN- 16 (30) 5 (31)
0.8331
3.8
0.0489
Any positive 38 (70) 13 (34) 4.3
∑CA repeats<34 30 (52) 14 (47)
0.0195
3.3
0.1505
∑CA repeats ≥34 28 (48) 5 (18) 4.8
EGFR IHC absent 40 (46) 19 (48)
0.3869
2.4
0.0680
EGFR IHC present 47 (54) 18 (38) 4.2
EGFR-PTEN- 16 (21) 6 (38)
0.8180
2.9
0.0290
Any positive 59 (79) 24 (41) 4.0
EGFR-pAKT- 18 (24) 9 (50)
0.3205
2.4
0.0607
Any positive 57 (76) 21 (37) 3.7
CEN7 polysomy <3.6/cell 63 (78) 29 (46)
0.0698
2.9
0.3461
CEN7 polysomy ≥3.6/cell 18 (22) 4 (22) 4.2
EGFR-CEN7- 31 (38) 15 (48)
0.2701
2.4
0.1180
Any positive 50 (62) 18 (36) 4.0
FISH- 45 (56) 20 (44)
0.4482
2.6
0.9607
FISH+ 36 (44) 13 (36) 3.9
